Precipio, Inc.
PRPO Healthcare Diagnostics & Research
Precipio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.0 million, up 29.8% from fiscal 2024. In the quarter to June 2026, revenue grew 24.2%, EPS fell 340.0%, free cash flow grew 79.6% and total debt rose 47.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PRPO
Precipio, Inc. (PRPO) Beneish M-score
Precipio, Inc.'s Beneish M-score for fiscal 2025 is −1.62; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −1.62 | 2.62 |
| FY2024 | −4.23 | (1.41) |
| FY2023 | −2.82 | 0.21 |
| FY2022 | −3.03 | (0.13) |
| FY2021 | −2.91 | 0.03 |
| FY2020 | −2.94 | 0.39 |
| FY2019 | −3.33 | 0.41 |
| FY2018 | −3.74 | (31.74) |
| FY2017 | 27.99 | 38.31 |
| FY2016 | −10.32 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 1.91 | — | 1.76 | |
| Gross margin index | 0.92 | — | 0.48 | |
| Asset quality index | 0.90 | — | 0.37 | |
| Sales growth index | 1.30 | — | 1.16 | |
| Depreciation index | 0.96 | — | 0.11 | |
| SG&A index SG&A not reported — index set to 1 | 1.00 | — | Set to 1 | −0.17 |
| Total accruals to total assets | (0.05) | — | −0.23 | |
| Leverage index | 0.77 | — | −0.25 | |
| Beneish M-score | Flagged by the model | −1.62 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| IMDX Insight Molecular Diagnostics Inc. compare | −7.7× |
| QUCY Quantum Cyber N.V compare | −6.1× |
| PMD Psychemedics Corporation compare | −4.4× |
| MDXH MDxHealth SA compare | −3.5× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | −2.5× |
| PRPO Precipio, Inc. | −1.6× |
| MDXHF MedX Health Corp. compare | — |
| ADVB Advanced Biomed Inc. compare | — |
| MBAI MBody AI Ltd. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI